Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Ma, Xueleia; 1 | Huang, Jingwenb; 1 | Wu, Xinc; 1 | Li, Xiec; 1 | Zhang, Jingb | Xue, Luqia | Li, Pingc | Liu, Leia; *
Affiliations: [a] State Key Laboratory of Biotherapy and Cancer Center, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China | [b] West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China | [c] Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Correspondence: [*] Corresponding authors: Lei Liu and Li Ping, Medical Oncology, West China Hospital, 37 Guoxuexiang Street, Chengdu 610000, Sichuan, China. Tel.: +86 13880768879; Fax: +86 2885164060; E-mail: liuleihx@gmail.com.
Note: [1] These authors contributed equally to the study.
Abstract: Background:Epidermal growth factor receptor (EGFR) has been reported to play a prognostic role in nasopharyngeal carcinoma (NPC). Nevertheless, the effect of EGFR predicting clinical outcomes is still controversial. Methods:Potentially eligible studies were retrieved using PubMed. Basic clinical characteristics of patients and statistical data were collected. Survival data can be got directly or could be calculated if it was available in other resources. Then, we used a meta-analysis model to review the correlation between over-expression of EGFR and survival outcome in NPC patients. Results:15 eligible studies and 1225 patients were yielded in our meta-analysis. The HRs with 95% confidence intervals (CIs) for OS and DFS/RFS/PFS were 2.11 [1.23, 3.60] and 2.17 [1.41, 3.35], respectively. Histological differentiation stage, race, different cut-off values and the percentage of TNM stage were divided for subgroup analysis. Conclusion:EGFR could be a fine prognostic factor of NPC, which might be proven by further multicenter clinical trials.
Keywords: EGFR, nasopharyngeal carcinoma, meta-analysis, prognosis
DOI: 10.3233/CBM-140401
Journal: Cancer Biomarkers, vol. 14, no. 4, pp. 267-277, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl